Yoğun Bakımda Kişiselleştirilmiş Tıp: Fenotiplendirme ile Hedefe Yönelik Tedaviler
References
Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801–810. doi:10.1001/jama.2016.0287
Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395(10219):200–211. doi:10.1016/S0140-6736(19)32989-7
Li Y, Yue Y, Lu Z, et al. Artificial intelligence and machine learning in acute respiratory distress syndrome management: recent advances. Front Med (Lausanne). 2025;12:1597556. doi:10.3389/fmed.2025.1597556
Lazar AE, Azamfirei L. Personalized Medicine for the Critically Ill Patient: A Narrative Review. Processes. 2022;10(6):1200. doi:10.3390/pr10061200
Gordon AC, Alipanah-Lechner N, Bos LD, et al. From ICU syndromes to ICU subphenotypes: consensus report and recommendations for developing precision medicine in the ICU. Am J Respir Crit Care Med. 2024;210(2):155–166. doi:10.1164/rccm.202311-2086SO
Seymour CW, Kennedy JN, Wang S, et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA. 2019;321(20):2003–2017. doi:10.1001/jama.2019.5791
Komorowski M, Celi LA, Badawi O, et al. The Artificial Intelligence Clinician learns optimal treatment strategies for sepsis in intensive care. Nat Med. 2018;24(11):1716–1720. doi:10.1038/s41591-018-0213-5
Antcliffe DB, Burnham KL, Al-Beidh F, et al. Transcriptomic signatures in sepsis and a differential response to steroids from the VANISH randomized trial. Am J Respir Crit Care Med. 2019;199(8):980–986. doi:10.1164/rccm.201807-1419OC
Davenport EE, Burnham KL, Radhakrishnan J, et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir Med. 2016;4(4):259-271. doi:10.1016/S2213-2600(16)00046-1
Famous KR, Delucchi K, Ware LB, et al. Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med. 2017;195(3):331–338. doi:10.1164/rccm.201603-0645OC
Kyriazopoulou E, Leventogiannis K, Norrby-Teglund A, et al. Toward personalized immunotherapy in sepsis: the PROVIDE randomized clinical trial. Cell Rep Med. 2022;3(11):100817. doi:10.1016/j.xcrm.2022.100817
Wilson, J.G., Calfee, C.S. ARDS Subphenotypes: Understanding a Heterogeneous Syndrome. Crit Care 24, 102 (2020). https://doi.org/10.1186/s13054-020-2778-x
Maddali MV, Churpek M, Pham T, et al. Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis. Lancet Respir Med. 2022;10(4):367-377. doi:10.1016/S2213-2600(21)00461-6
Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395(10219):200–211. doi:10.1016/S0140-6736(19)32989-7
Li Y, Yue Y, Lu Z, et al. Artificial intelligence and machine learning in acute respiratory distress syndrome management: recent advances. Front Med (Lausanne). 2025;12:1597556. doi:10.3389/fmed.2025.1597556
Lazar AE, Azamfirei L. Personalized Medicine for the Critically Ill Patient: A Narrative Review. Processes. 2022;10(6):1200. doi:10.3390/pr10061200
Gordon AC, Alipanah-Lechner N, Bos LD, et al. From ICU syndromes to ICU subphenotypes: consensus report and recommendations for developing precision medicine in the ICU. Am J Respir Crit Care Med. 2024;210(2):155–166. doi:10.1164/rccm.202311-2086SO
Seymour CW, Kennedy JN, Wang S, et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA. 2019;321(20):2003–2017. doi:10.1001/jama.2019.5791
Komorowski M, Celi LA, Badawi O, et al. The Artificial Intelligence Clinician learns optimal treatment strategies for sepsis in intensive care. Nat Med. 2018;24(11):1716–1720. doi:10.1038/s41591-018-0213-5
Antcliffe DB, Burnham KL, Al-Beidh F, et al. Transcriptomic signatures in sepsis and a differential response to steroids from the VANISH randomized trial. Am J Respir Crit Care Med. 2019;199(8):980–986. doi:10.1164/rccm.201807-1419OC
Davenport EE, Burnham KL, Radhakrishnan J, et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir Med. 2016;4(4):259-271. doi:10.1016/S2213-2600(16)00046-1
Famous KR, Delucchi K, Ware LB, et al. Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med. 2017;195(3):331–338. doi:10.1164/rccm.201603-0645OC
Kyriazopoulou E, Leventogiannis K, Norrby-Teglund A, et al. Toward personalized immunotherapy in sepsis: the PROVIDE randomized clinical trial. Cell Rep Med. 2022;3(11):100817. doi:10.1016/j.xcrm.2022.100817
Wilson, J.G., Calfee, C.S. ARDS Subphenotypes: Understanding a Heterogeneous Syndrome. Crit Care 24, 102 (2020). https://doi.org/10.1186/s13054-020-2778-x
Maddali MV, Churpek M, Pham T, et al. Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis. Lancet Respir Med. 2022;10(4):367-377. doi:10.1016/S2213-2600(21)00461-6
Pages
1-18
Published
April 15, 2026
Copyright (c) 2026 Academician Publishing Book Portal
